1.Discussion on the Wenzi Jiedu Method for Treating Malignant Tumors Based on the Theory of Circulation of Phase Fire
Yutian GU ; Hongguang ZHOU ; Hao LI ; Xinyan DAI ; Yan SHAO ; Huan YANG ; Weichen YUAN
Journal of Nanjing University of Traditional Chinese Medicine 2025;41(5):567-575
Based on the theory of circulation of qi,a theoretical model of the circulation of phase fire in the human body was con-structed.It is proposed that cancer toxicity is the key factor that triggers the disorder of phase fire and hinders the circulation of phase fire.The disorder of phase fire and poor circulation are important pathogenesis of the occurrence and development of cancer toxicity.With the principle of strengthening healthy qi and eliminating evil qi,the Wenzi Jiedu method is used to treat tumors,which plays an important role in warming and nourishing,regulating yin and yang,and eliminating cancer toxicity.The combination of war-ming,nourishing and detoxification can promote the return of the phase fire and make the human body's generation and transformation active,providing a new treatment idea for TCM diagnosis and treatment of tumors with mainly cold poison or mixed cold and heat.
2.Current Status,Advantages and Strategies of TCM in the Prevention and Treatment of Malignant Tumors
Weichen YUAN ; Hongguang ZHOU ; Wenting LI ; Li LI ; Muhan LI ; Mianhua WU
Journal of Nanjing University of Traditional Chinese Medicine 2025;41(6):707-720
This paper summarizes the current status of research on the prevention and treatment of malignant tumors with traditional Chinese medicine(TCM),and points out that TCM has the advantages of being based on the holistic view and advocating the preven-tive treatment of diseases.The strategies of TCM in preventing and treating malignant tumors are proposed:first,it is necessary to clar-ify the leading or auxiliary treatment role in different stages of tumors and give full play to its strengths and advantages;second,find the characteristics of the superior and inferior populations and microscopic markers of tumor diagnosis and treatment to promote accurate di-agnosis and treatment;third,improve the overall diagnosis and treatment level of tumors by grasping the core pathogenesis and ensure clinical efficacy;fourth,incorporate modern medical therapy factors into the TCM tumor diagnosis and treatment system in order to in-tercept the disease;fifth,add TCM psychological intervention on the basis of the four-in-one holistic syndrome differentiation view to achieve harmony between body and spirit;sixth,improve the rehabilitation and health care system of tumors combined with traditional Chinese and Western medicine through the use of multiple methods to promote the recovery of diseases.In this way,the clinical effica-cy of TCM in preventing and treating tumors can be continuously improved,and the great goal of TCM in preventing and treating tumors and benefiting all mankind can be truly realized.
3.Study on the Mechanism of Anti-Colorectal Cancer Effects of Anzheng Kangliu Decoction by Inhibiting Glycolysis via PI3K/Akt/mTOR Pathway
Yuwei LIANG ; Hongli ZHOU ; Yupei ZHUANG ; Weichen YUAN ; Mingjun TANG ; Wenting LI ; Li LI ; Mianhua WU
Journal of Nanjing University of Traditional Chinese Medicine 2025;41(6):730-741
OBJECTIVE To investigate the inhibitory effect mechanism of Anzheng Kangliu Decoction against colorectal cancer by suppressing glycolysis through regulation of the phosphatidylinositol 3-kinase(PI3K)/protein kinase B(Akt)/mammalian target of rapamycin(mTOR)signaling pathway.METHODS Human colorectal cancer SW620 cells were treated with Anzheng Kangliu De-coction,and cell proliferation and migration abilities were assessed.Forty-two BALB/c nude mice were randomly divided into a blank control group,model group,5-fluorouracil(5-FU)group(0.025 g·kg-1),Anzheng Kangliu Decoction low-dose group(7.67 g·kg-1),medium-dose group(15.34 g·kg-1),and high-dose group(30.68 g·kg-1).The inhibitory effect of Anzheng Kan-gliu Decoction on subcutaneous xenograft tumors was evaluated by observing body weight,tumor volume,tumor mass,HE staining,im-munohistochemical staining of Ki67 and other indicators.High-throughput transcriptome sequencing was performed to identify differen-tially expressed genes and pathways in tumor tissues between the model group and the Anzheng Kangliu Decoction medium-dose group,elucidating the potential mechanism of Anzheng Kangliu Decoction against colorectal cancer.Glucose and lactate assay kits were used to measure glucose consumption and lactate production in SW620 cells and tumor tissues after Anzheng Kangliu Decoction intervention.Western blot was employed to detect the expression levels of p-PI3K/PI3K,p-Akt/Akt,p-mTOR/mTOR,hexokinase 2(HK2),and lactate dehydrogenase A(LDHA)in SW620 cells and tumor tissues following Anzheng Kangliu Decoction treatment.RE-SULTS In vitro cell experiments demonstrated that,compared with the blank control group,Anzheng Kangliu Decoction intervention significantly inhibited the proliferation and migration of SW620 cells(P<0.01),reduced glucose consumption and lactate production(P<0.05,P<0.01),and downregulated the protein expression levels of p-PI3K/PI3K,p-Akt/Akt,p-mTOR/mTOR,HK2,and LDHA(P<0.05,P<0.01).In vivo animal experiments revealed that,compared with the model group,Anzheng Kangliu Decoction suppressed the growth of subcutaneous xenograft tumors in nude mice(P<0.01),increased tumor tissue necrosis,decreased glucose consumption and lactate production in tumor tissues(P<0.05,P<0.01),and reduced the protein expression levels of p-PI3K/PI3K,p-Akt/Akt,p-mTOR/mTOR,HK2,and LDHA(P<0.05,P<0.01).CONCLUSION Anzheng Kangliu Decoction exerts an in-hibitory effect on colorectal cancer,and its mechanism may be associated with the suppression of glycolysis through regulation of the PI3K/Akt/mTOR signaling pathway.
4.Research progress in antibody drug therapy for relapsed/refractory diffuse large B-cell lymphoma
Yanyan SUN ; Weichen ZHAO ; Chunyuan HE ; Yimiao XIA ; Wei ZHOU ; Yuanyuan ZHEN ; Junjie JIANG ; Facai WANG
China Pharmacy 2025;36(13):1677-1682
Diffuse large B-cell lymphoma(DLBCL)is a highly heterogeneous disease.Although standard first-line regimens can cure>50%of patients,approximately one-third of them develop relapsed/refractory DLBCL(r/r DLBCL).Consequently,immunotherapy targeting molecular abnormalities has become pivotal for managing r/r DLBCL.The results of this review show that with advances in understanding DLBCL pathogenesis and the tumor immune microenvironment,antibody-based therapies have evolved rapidly,progressing from monoclonal antibodies(e.g.,rituximab,tafasitamab)to bispecific antibodies(e.g.,odronextamab,glofitamab,epcoritamab)and antibody-drug conjugate(e.g.,polatuzumab vedotin,loncastuximab tesirine).These engineered agents enhance immune cytotoxicity and tumor-specific targeting,providing novel therapeutic options for r/r DLBCL patients.
5.Risk factors for slow-flow or no-reflow during percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction:a meta-analysis
Yunfei ZHANG ; Wenjuan YAN ; Hongmei WEN ; Weichen CHEN ; Hongjuan ZHOU ; Qiong HAN ; Jiaoyang XU ; Yingfeng LI
Journal of Interventional Radiology 2025;34(3):243-252
Objective Using meta-analysis to identify the risk factors for slow-flow or no-reflow during percutaneous coronary intervention(PCI)in patients with ST-segment elevation acute myocardial infarction(AMI).Methods A computerized retrieval of academic papers concerning the risk factors for slow-flow or no-reflow during PCI in patients with ST-segment elevation AMI from the databases of CNKI,Wanfang Database,VIP,SinoMed,PubMed,Web of Science,Embase,and Cochrane Library was conducted.The retrieval time period was from the establishment of the database to January 2024.In order to ensure the accuracy and reliability of the study,two independent reviewers screened the literature according to the preset inclusion and exclusion criteria,extracted key data,and strictly evaluated the quality of the literature.RevMan5.4 software was used to make meta-analysis.Results A total of 23 articles with a total of 9 780 cases were included in this analysis.The results of meta-analysis showed that reperfusion time ≥6 h(OR=1.52),preoperative TIMI blood flow≤level-Ⅰ(OR=1.12),heavy thrombus burden(OR=1.60),advanced age(OR=1.56),diabetes(OR=1.83),preoperative Killip grade≥Ⅲ(OR=2.52),long target vessel disease(OR=1.95),and collateral flow≤level-Ⅰ(OR=1.61)were the risk factors for slow-flow or no-reflow during PCI in patients with ST-segment elevation AMI.Preoperative systolic blood pressure<90 mmHg(OR=1.17)and high white blood cell(WBC)count(OR=1.27)were not the risk factors for slow-flow or no-reflow during PCI in patients with ST-segment elevation AMI.Conclusion Reperfusion time ≥ 6 h,preoperative TIMI blood flow≤level-Ⅰ,heavy thrombus burden,advanced age,diabetes,preoperative Killip grade≥level-Ⅲ,long target vessel lesion,and collateral blood flow≤level-Ⅰ are the independent risk factors for slow-flow or no-reflow during PCI in patients with ST-segment elevation AMI.
6.Discussion on the Wenzi Jiedu Method for Treating Malignant Tumors Based on the Theory of Circulation of Phase Fire
Yutian GU ; Hongguang ZHOU ; Hao LI ; Xinyan DAI ; Yan SHAO ; Huan YANG ; Weichen YUAN
Journal of Nanjing University of Traditional Chinese Medicine 2025;41(5):567-575
Based on the theory of circulation of qi,a theoretical model of the circulation of phase fire in the human body was con-structed.It is proposed that cancer toxicity is the key factor that triggers the disorder of phase fire and hinders the circulation of phase fire.The disorder of phase fire and poor circulation are important pathogenesis of the occurrence and development of cancer toxicity.With the principle of strengthening healthy qi and eliminating evil qi,the Wenzi Jiedu method is used to treat tumors,which plays an important role in warming and nourishing,regulating yin and yang,and eliminating cancer toxicity.The combination of war-ming,nourishing and detoxification can promote the return of the phase fire and make the human body's generation and transformation active,providing a new treatment idea for TCM diagnosis and treatment of tumors with mainly cold poison or mixed cold and heat.
7.Current Status,Advantages and Strategies of TCM in the Prevention and Treatment of Malignant Tumors
Weichen YUAN ; Hongguang ZHOU ; Wenting LI ; Li LI ; Muhan LI ; Mianhua WU
Journal of Nanjing University of Traditional Chinese Medicine 2025;41(6):707-720
This paper summarizes the current status of research on the prevention and treatment of malignant tumors with traditional Chinese medicine(TCM),and points out that TCM has the advantages of being based on the holistic view and advocating the preven-tive treatment of diseases.The strategies of TCM in preventing and treating malignant tumors are proposed:first,it is necessary to clar-ify the leading or auxiliary treatment role in different stages of tumors and give full play to its strengths and advantages;second,find the characteristics of the superior and inferior populations and microscopic markers of tumor diagnosis and treatment to promote accurate di-agnosis and treatment;third,improve the overall diagnosis and treatment level of tumors by grasping the core pathogenesis and ensure clinical efficacy;fourth,incorporate modern medical therapy factors into the TCM tumor diagnosis and treatment system in order to in-tercept the disease;fifth,add TCM psychological intervention on the basis of the four-in-one holistic syndrome differentiation view to achieve harmony between body and spirit;sixth,improve the rehabilitation and health care system of tumors combined with traditional Chinese and Western medicine through the use of multiple methods to promote the recovery of diseases.In this way,the clinical effica-cy of TCM in preventing and treating tumors can be continuously improved,and the great goal of TCM in preventing and treating tumors and benefiting all mankind can be truly realized.
8.Study on the Mechanism of Anti-Colorectal Cancer Effects of Anzheng Kangliu Decoction by Inhibiting Glycolysis via PI3K/Akt/mTOR Pathway
Yuwei LIANG ; Hongli ZHOU ; Yupei ZHUANG ; Weichen YUAN ; Mingjun TANG ; Wenting LI ; Li LI ; Mianhua WU
Journal of Nanjing University of Traditional Chinese Medicine 2025;41(6):730-741
OBJECTIVE To investigate the inhibitory effect mechanism of Anzheng Kangliu Decoction against colorectal cancer by suppressing glycolysis through regulation of the phosphatidylinositol 3-kinase(PI3K)/protein kinase B(Akt)/mammalian target of rapamycin(mTOR)signaling pathway.METHODS Human colorectal cancer SW620 cells were treated with Anzheng Kangliu De-coction,and cell proliferation and migration abilities were assessed.Forty-two BALB/c nude mice were randomly divided into a blank control group,model group,5-fluorouracil(5-FU)group(0.025 g·kg-1),Anzheng Kangliu Decoction low-dose group(7.67 g·kg-1),medium-dose group(15.34 g·kg-1),and high-dose group(30.68 g·kg-1).The inhibitory effect of Anzheng Kan-gliu Decoction on subcutaneous xenograft tumors was evaluated by observing body weight,tumor volume,tumor mass,HE staining,im-munohistochemical staining of Ki67 and other indicators.High-throughput transcriptome sequencing was performed to identify differen-tially expressed genes and pathways in tumor tissues between the model group and the Anzheng Kangliu Decoction medium-dose group,elucidating the potential mechanism of Anzheng Kangliu Decoction against colorectal cancer.Glucose and lactate assay kits were used to measure glucose consumption and lactate production in SW620 cells and tumor tissues after Anzheng Kangliu Decoction intervention.Western blot was employed to detect the expression levels of p-PI3K/PI3K,p-Akt/Akt,p-mTOR/mTOR,hexokinase 2(HK2),and lactate dehydrogenase A(LDHA)in SW620 cells and tumor tissues following Anzheng Kangliu Decoction treatment.RE-SULTS In vitro cell experiments demonstrated that,compared with the blank control group,Anzheng Kangliu Decoction intervention significantly inhibited the proliferation and migration of SW620 cells(P<0.01),reduced glucose consumption and lactate production(P<0.05,P<0.01),and downregulated the protein expression levels of p-PI3K/PI3K,p-Akt/Akt,p-mTOR/mTOR,HK2,and LDHA(P<0.05,P<0.01).In vivo animal experiments revealed that,compared with the model group,Anzheng Kangliu Decoction suppressed the growth of subcutaneous xenograft tumors in nude mice(P<0.01),increased tumor tissue necrosis,decreased glucose consumption and lactate production in tumor tissues(P<0.05,P<0.01),and reduced the protein expression levels of p-PI3K/PI3K,p-Akt/Akt,p-mTOR/mTOR,HK2,and LDHA(P<0.05,P<0.01).CONCLUSION Anzheng Kangliu Decoction exerts an in-hibitory effect on colorectal cancer,and its mechanism may be associated with the suppression of glycolysis through regulation of the PI3K/Akt/mTOR signaling pathway.
9.Construction of Detoxication Method of Warming and Nourishing under the Guidance of Compound Pathogenesis Theory of Malignant Tumor
Weichen YUAN ; Hongguang ZHOU ; Yupei ZHUANG ; Hongli ZHOU ; Mianhua WU
Journal of Nanjing University of Traditional Chinese Medicine 2024;40(6):543-549
Based on the compound pathogenesis theory of malignant tumor,this article combines the theories of positive-evil,yin-yang,and central qi theories with the theory of cancer toxin,pointing out that the deficiency of positive and excess of evil are the basis for the onset of tumors.The pathogenesis characteristics of tumors are the loss of both yin and yang,stagnation of qi,and cancer toxin deeply lurking.The paper believes that the loss of both yin and yang often originates from the spleen and kidney,stagnation of qi is first blamed on the spleen and stomach,and cancer toxin deeply lurking often accompanies multiple evil qi.Based on this,the detoxi-cation method of warming and nourishing is proposed to treat malignant tumors.It is the combination or sequential application of the three methods of warming,nourishing,and detoxification,which play the role of warming and nourishing together,harmonizing yin and yang;promoting the circulation of qi,relieving depression,and regulating emotions;eliminating cancer and toxin,and breaking the combined evil.
10.RASAL3 promotes the proliferation of intrahepatic cholangiocarcinoma cells by up regulating the expression of FXYD6
Bin ZHANG ; Dachen ZHOU ; Zhongbiao CHEN ; Weichen WANG ; Hui HOU ; Qiru XIONG ; Guoqiang PING
Chinese Journal of General Surgery 2022;37(11):839-844
Objective:To investigate the expression of RASAL3 in intrahepatic cholangiocarcinoma (iCCA) and the mechanism of promoting iCCA development.Methods:Tumor and paracancerous tissues were collected from 185 iCCA patients, the expression of RASAL3 was detected by immunohistochemistry, RT-qPCR and Western blot. The expression of RASAL3 and FXYD6 mRNA and protein in human cholangiocarcinoma cell line and human bile duct epithelial cells were detected with RT-qPCR and Western blot, the cell proliferation was detected with CCK-8 assay, and the activity of Na +-K +-ATPase was also detected. Results:RASAL3 was highly expressed in cholangiocarcinoma tissues and cell lines; Survival analysis showed that RASAL3 overexpression was associated with poor prognosis of cholangiocarcinoma( P<0.05) and knockdown of RASAL3 inhibits the proliferation of cholangiocarcinoma cells; Silencing RASAL3 decreases the expression of FXYD6 inhibiting the activity of Na +-K +-ATPase. Conclusion:RASAL3 is up-regulated in human cholangiocarcinoma, which can promote the occurrence and development of cholangiocarcinoma by activating FXYD6 and affecting Na +-K +-ATPase activity.

Result Analysis
Print
Save
E-mail